Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Research Analysts Set Expectations for LPTX FY2029 Earnings
Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Leap Therapeutics in a research report ...
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...
Leap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancer
Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral
H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...
American Association of Individual Investors10d
Why Leap Therapeutics, Inc.’s (LPTX) Stock Is Down 71.11%
Leap Therapeutics, Inc.’s LPTX share price has dipped by 71.11%, which has investors questioning if this is right time to buy ...
Leap Therapeutics reports initial data from DeFianCe, DisTinGuish studies
Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with ...
Leap Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data ...
Morningstar22d
Leap Therapeutics Inc LPTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...